Stock Ratings / Health Care / GRI / financials

ERNA (46) ONCO (36) CVKD (40) EOCN (47) ⌘ Pro Terminal →

GRI Bio Inc. (GRI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.57 -3.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

GRI Bio Inc. (GRI) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRI)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How GRI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.3%	-$12.0M	-$10.2M	-45%
FY 2024	$4.00B	52%	-0.2%	-$8.2M	-$8.6M	-45%
FY 2023	$4.00B	52%	-0.3%	-$13.0M	-$9.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRI)

✓Walkthrough of GRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.98%📐 HORIZONTAL RANGE

2026-10-30O $1.59H $1.59L $1.45C $1.57VOL 28.7K

RES: $3.81SUP: $1.36SMA50: $1.82SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRI Butterfly Map → + Track GRI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRI)

Health Care Rank #735 of 1016 ⚔️ ERNA vs GRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRI vs. ERNA, ONCO, CVKD, EOCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GRI Bio Inc. (GRI) ranks #735 by composite RQD confidence (38/100, grade D-) and #973 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, GRI leads on earnings valuation at N/A trailing P/E, while GRI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EOCN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with GRI at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRI ACTIVE GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	Benchmark Subject
ERNA Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	/erna-vs-gri →
ONCO Onconetix Inc.	D-	36/100	—	77.6%	-35.0%	-1.99%	$3.5M	/onco-vs-gri →
CVKD Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	/cvkd-vs-gri →
EOCN Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	/eocn-vs-gri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824293

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GRI Bio Inc. (GRI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.0M, operating cash flow of -$10.2M, and free cash flow of -$10.2M (-18.3% YoY). On the balance sheet, GRI closed FY2025 with $8.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.0M	-$10.2M	-$10.2M	$8.7M	—
FY2024 (FY)	2024-12-31	$0	-$8.2M	-$8.6M	-$8.6M	$5.7M	—
FY2023 (FY)	2023-12-31	$0	-$13.0M	-$9.0M	-$9.0M	—	—

3. GRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, GRI Bio Inc. (NASDAQ: GRI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.57 (-3.38% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GRI ranks #735 in composite RQD confidence.

How does GRI compare to ERNA and ONCO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRI carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, GRI leads on earnings multiple (N/A) while GRI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRI?

Per GRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824293), GRI Bio Inc. generated $0 in revenue, -$12.0M in net income, and -$10.2M in free cash flow against $8.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRI trading relative to its 50-day, 200-day, and 52-week technical levels?

GRI last traded at $1.57 (-3.38% on volume of 23,073 shares), positioning the stock -13.74% below its 50-day simple moving average ($1.82) and -29.91% below its 200-day simple moving average ($2.24). Across its 52-week range of $1.36 to $64.12, GRI sits at the 0.3% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.37 to $1.77).